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Recent epidemiological studies have shown a J-shaped
association between the risk of stroke and systolic blood
pressure (SBP) levels in people with chronic kidney disease
(CKD). The Perindopril Protection Against Recurrent Stroke
Study (PROGRESS) was a randomized, placebo-controlled trial
demonstrating that perindopril-based blood pressure (BP)
lowering reduced the risk of stroke in 6105 participants with
prior cerebrovascular disease. We estimated the effects of
therapy on the risk of recurrent stroke in 1757 of these
participants with stage 3 or greater CKD according to
baseline BP and the relationship between achieved follow-up
BP and the risk of stroke. Active therapy produced
comparable and significant reductions in the risk of stroke
across all baseline SBP levels. The age- and gender-adjusted
incidence of stroke increased significantly in a log-linear
relationship for achieved SBP levels and strokes per 1000
person-years. This association persisted after adjusting for
potential confounding factors. We found that perindopril-
based BP lowering effectively prevented recurrent stroke in
people with CKD, across a wide range of BP levels, without
evidence of an increased risk of stroke in people with low BP
levels.
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Chronic kidney disease (CKD) affects 10–15% of the adult
population in western countries1,2 and is associated with an
increased risk of cardiovascular (CV) events,3 in particular
stroke.4,5 Blood pressure (BP) is an important determinant of
the risk of stroke in the general population,6 where it has
been well established that interventions to lower BP prevent
CV disease.7,8 These benefits have been demonstrated for
high-risk subjects across a wide range of BP levels,9 including
those with ‘normal’ BP.
Blood pressure is commonly elevated in people with CKD
and is associated with an increased risk of CV events,
suggesting that BP lowering may offer significant benefits in
this patient group. Recent observational studies, however,
have suggested that the risk of stroke and death of people
with CKD may be greater among those with systolic blood
pressure (SBP) levels below 120 mm Hg than among those
with higher levels.10,11 Furthermore, trials examining the
effects of regimens targeting lower BP levels in those with
CKD have not demonstrated clear benefits on CV end
points.12,13 These data have raised concerns that BP lowering
might have less benefit, or even be hazardous, in the high-risk
individuals with CKD who do not have substantially elevated
BP levels.
In this study, we present results from the Perindopril
Protection Against Recurrent Stroke Study (PROGRESS), a
large placebo-controlled trial of a BP lowering regimen based
on the angiotensin-converting enzyme inhibitor perindopril
in patients with a prior cerebrovascular event. Our aim was to
assess the balance of risks and benefits associated with BP
lowering across a broad range of BP levels in those people
with reduced kidney function at entry to the trial.
RESULTS
Baseline characteristics
Among 6071 participants recruited to the PROGRESS study,
whose baseline kidney function data were available, 724
suffered a stroke during an average of 3.9 years of follow-up,
of which 589 (81.4%) were confirmed by radiographic
examinations and/or autopsy findings. Two participants from
the active treatment group and one participant from the
placebo group were lost to follow-up. There were 1757
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(28.9%) participants who had CKD at entry to the study and
264 of them experienced stroke during follow-up. The
majority of participants with CKD had stage 3 disease
(1695/1757 (96.5%)) and a small number had stage 4 CKD
(62/1757 (3.5%)). Among participants with CKD, the
creatinine clearance at baseline ranged from 20.3 to
59.9 ml min1.
Table 1 shows the baseline characteristics of participants
overall, and according to the presence of CKD at baseline. On
average, those with CKD at baseline were older, had a lower
body mass index, and had a higher SBP, but a lower diastolic
blood pressure (DBP) than those without CKD. In addition,
participants with CKD were more likely to be female,
receiving background BP-lowering medication, less likely to
have diabetes or to smoke cigarettes, and less likely to have
received combination therapy than those without CKD.
Effects of randomized treatment
The administration of a perindopril-based BP-lowering
regimen produced similar reductions in the risk of stroke
in both the CKD and non-CKD groups, and across groups
with SBP o140, 140–159, and X160 mm Hg at baseline
(Figure 1). Active treatment reduced the risk of stroke by
about 30% in both the CKD and non-CKD groups. The
magnitude of the effect of active treatment for stroke was
similar across the three baseline SBP levels in both the CKD
(P heterogeneity¼ 0.21) and non-CKD groups (P hetero-
geneity¼ 0.15). Even in people with CKD and an SBP below
140 mm Hg, a borderline statistically significant risk reduc-
tion for stroke was observed (hazard ratio 0.65 (95%
confidence interval (CI) 0.42–1.00), P¼ 0.05). There was no
evidence of heterogeneity for the effects of treatment on the
risk of stroke between participants with and without CKD at
each baseline BP level (all P heterogeneity 40.2). Similar
results were observed in analyses according to baseline DBP
levels (Figure 1), and according to stroke subtype (Figure 2).
No clear differences were observed in the benefit achieved
with active therapy for hemorrhagic stroke across all kidney
function and BP subgroups; however, the small number of
such strokes observed during follow-up means that we had
limited statistical power to detect any such difference. As
recently reported, the effects of randomized therapy on other
major CV events including total mortality were similar in
people with and without CKD.14
Table 1 | Baseline characteristics of participants overall and according to kidney function
Overall (N=6071) CKD (N=1757) Non-CKD (N=4314) P-valuea
Age (years) 64 (10) 70 (8) 61 (9) o0.0001
Women (%) 30 45 25 o0.0001
Asianb (%) 38 37 39 0.4
Creatinine (mmol l1) 88 (75–100) 102 (88–120) 83 (71–95) o0.0001
Creatinine clearance (ml min1) 72 (58–89) 50 (45–56) 81 (70–96) o0.0001
SBP (mm Hg) 147 (19) 149 (20) 146 (19) o0.0001
DBP (mm Hg) 86 (11) 84 (11) 86 (11) o0.0001
SBP levels at baseline (%)
o140 mm Hg 35 30 37 o0.0001
140–159 mm Hg 39 39 39
X160 mm Hg 26 31 24
DBP levels at baseline (%)
o80 mm Hg 26 31 24 o0.0001
80–89 mm Hg 35 36 35
X90 mm Hg 39 33 41
Body mass index (kg m2) 26 (4) 24 (3) 26 (4) o0.0001
Diabetes (%) 13 11 13 0.01
Current smoker (%) 20 16 22 o0.0001
Medication
Antihypertensive therapy (%)c 50 53 49 0.002
Antiplatelet therapy (%) 72 73 72 0.3
Oral anticoagulants (%) 9 10 9 0.4
Lipid-lowering therapy (%) 14 12 15 0.006
Study treatment regimen
Active therapy (%) 50 51 50 0.3
Combination therapy or
double placebos (%)
58 54 60 o0.0001
CKD, chronic kidney disease; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Continuous variables are shown as mean (s.d.) or median (interquartile range).
aDifferences between patients with and without chronic kidney disease.
bParticipants recruited from People’s Republic of China or Japan.
cCurrent treated hypertension.
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Achieved follow-up BP levels and the risk of stroke according
to kidney function
A log-linear relationship between the age- and sex-adjusted
rates of stroke and the achieved follow-up SBP levels was
observed in both participants with and without CKD
(Figure 3). A similar pattern was observed after adjustment
for age, sex, smoking, diabetes, body mass index, study
treatment, and combination therapy, and when these analyses
were performed using achieved DBP (Figure 3). No
heterogeneity was detected in the relationship between
achieved follow-up BP and the risk of stroke between
participants with and without CKD (all P heterogeneity
40.2). The associations were similar for both ischemic and
hemorrhagic stroke (Figure 4).
DISCUSSION
In this study, perindopril-based BP-lowering therapy reduced
the risk of recurrent stroke in participants with coexisting
CKD and cerebrovascular disease across a wide spectrum of
baseline BP levels. Furthermore, the relationship between
achieved follow-up BP levels and the risk of stroke was shown
to be strong and continuous, with no evidence of a ‘J-curve.’
These findings suggest that lower BP targets (including those
below 120/80 mm Hg) may not be associated with an
increased risk of stroke, as has been recently suggested,10
but instead could be protective in high-risk people with
cerebrovascular disease.
These findings are consistent with those observed in
studies conducted in the general population, where the risk of
stroke doubles with each incremental rise of 20/10 mm Hg
above a baseline BP of 115/75 mm Hg.6 Recent publications
of observational data suggested that individuals with CKD
and a SBP o120 mm Hg were at increased risk of stroke or
death, even after adjustment for other relevant factors.10,11
Such findings are contrary to those in this study for
participants with and without CKD, to previous analyses of
BP levels 
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Figure 1 | Effects of randomized treatment on the risk of stroke according to baseline systolic or diastolic blood pressure levels in
patients with and without chronic kidney disease. Treatment effects in subgroup were standardized for the proportions of the
study population for whom combination (58%) or single-drug therapy (42%) was prescribed by taking weighted averages of the estimates
obtained for the two therapies. Solid boxes represent estimates of treatment effect on the risk of clinical outcomes. Centers of the boxes are
placed at the estimates of effect; areas of the boxes are proportional to the number of events. Horizontal lines represent 95% CI. Vertical broken
lines represent point estimates for overall effects. The ‘P trend’ tested the consistency of the treatment effect in CKD and non-CKD subgroups.
SBP/DBP difference indicates the mean reduction in SBP or DBP produced by randomized treatment. CKD, chronic kidney disease; CI,
confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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the overall PROGRESS study population,9 and to other
studies conducted in the general population.6 Other post hoc
analyses of trials conducted in individuals with coronary
disease15 and with diabetic nephropathy16 have found similar
results with no evidence to suggest an increased risk of stroke
in the lower BP groups, consistent with our results. However,
the analyses from these studies15,16 did suggest an increased
risk of coronary events at lower achieved BPs, a finding we
were unable to assess reliably due to the relatively small
number of coronary events in PROGRESS. One possible
explanation for the disparity between the results obtained
from observational studies compared to randomized trials is
the phenomenon of reverse causality,17–19 where extensive
vascular disease may be associated with lower BP levels,
reduced kidney function, and independently with a relatively
high risk of stroke recurrence, rather than from any adverse
effects of low BP itself. These individuals may therefore derive
substantial benefits from BP lowering, as the progression of
the underlying generalized vasculopathy may be reduced.
Further research is needed to define the optimal target BP
levels in people with CKD.
The PROGRESS study provides an important source of
data regarding the relationship between BP and stroke.
Participants in this trial had very high incidence of stroke
during several years of follow-up because of a established
cerebrovascular disease-based selection. Individuals were
enrolled with a wide range of baseline BP levels, as particular
BP levels were not part of the entry criteria. Although the
number of participants with CKD and an SBP below
120 mm Hg at baseline was relatively small, a significant
number of participants had baseline CKD and an SBP below
140 mm Hg. These individuals, whose follow-up SBP avera-
ged 126 mm Hg, experienced a 35% reduction in the risk of
stroke. The participants with CKD and the lowest achieved
follow-up BPs (particularly those with SBP levels below
120 mm Hg) had the lowest incidence of secondary stroke.
The benefits derived from lower achieved BP levels during
follow-up were similar regardless of the presence or absence
of CKD.
There are very few randomized trials of BP lowering
conducted specifically among individuals with CKD that
have provided conclusive data regarding effects on CV events.
The African American Study of Kidney Disease (AASK)
studied the effects of a lower BP treatment goal (mean BP
o92 mm Hg) among 1094 African-Americans with hyper-
tensive nephrosclerosis.12,13 Although no beneficial effect on
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Figure 2 | Effects of randomized treatment on the risk of subtype of stroke according to baseline systolic or diastolic blood
pressure levels in participants with chronic kidney disease. Conventions as for Figure 1.
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CV outcomes was identified, this could have been due to
limited statistical power. In addition, a recent long-term
follow-up of participants in the Modification of Diet in Renal
Disease (MDRD) study found that lower BP goals (BPo120/
80 mm Hg) were effective in reducing the risk of end-stage
kidney disease compared with usual BP goals (BP 140/
90 mm Hg).20 The current data, therefore, support the
achievement of lower BP for individual with CKD to reduce
the risk of CV disease and end-stage kidney disease. Although
more data are clearly required to guide optimal therapy, the
very high risk of stroke observed in the presence of CKD
highlights the importance of appropriate management of all
CV risk factors.
Several limitations of our study should be noted.
Although, to date, PROGRESS is the largest trial that has
investigated the effects of BP lowering in participants with
prior cerebrovascular disease, the power to conduct detailed
subgroup analyses is limited. Second, as all participants in
PROGRESS had preexisting cerebrovascular disease, there are
limits to the generalizability of the findings to other high-risk
groups, despite our findings being similar to previous studies
examining the effects of BP-lowering therapy on the
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Figure 3 | Age- and sex-adjusted incidence rates or multivariate-adjusted hazard ratios of total stroke according to achieved
follow-up systolic or diastolic blood pressure levels. Solid boxes or open boxes represent the estimates of incidence rates or hazard ratios of
total stroke according to the presence or absence of CKD, respectively. Centers of the boxes are placed at the estimates of incidence rate or
hazard ratios; areas of the boxes are proportional on the number of events. Vertical lines represent 95% confidence intervals. Boxes offset
from each other for clarify. The hazard ratios were estimated using time-dependent Cox’s proportional hazards model that contained dummy
variables for CKD and BP levels and potential confounding factors (baseline age, sex, smoking, diabetes, body mass index, study treatment,
and combination therapy). The reference group is participants with CKD and SBP 120–139 mm Hg. The trends of the relationship of
achieved follow-up BP levels with events were tested by kidney function status. CKD, chronic kidney disease; CI, confidence interval.
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prevention of stroke.7,21 Third, the applicability of these
results to populations with advanced CKD is limited because
only 1% of all participants had a creatinine clearance of
30 ml min1 or less. Moreover, the absence of data on
proteinuria in this trial makes it impossible to assess the
effects of therapy on the risk of stroke in the earliest stages of
CKD. Finally, the creatinine measurements were conducted
locally rather than at a central laboratory, introducing a
source of variability that may reduce the precision of the
results.
In conclusion, these data suggest that BP-lowering
treatment is effective in preventing recurrent stroke across a
broad range of BP levels in individuals with coexisting CKD
and cerebrovascular disease. Furthermore, a continuous
relationship between achieved follow-up BP and the risk of
stroke was observed without evidence of a J-curve in either
the CKD or the non-CKD populations. In both cases, the risk
of recurrent stroke was lowest when follow-up SBP was below
120 mm Hg. Optimizing BP control in high-risk individuals
with CKD is therefore likely to reduce substantially the
burden of cerebrovascular disease in the population.
MATERIALS AND METHODS
Overview
The design of the PROGRESS study has been described in detail
elsewhere.22 In brief, 6105 patients with a history of a cerebrovas-
cular disease within the previous 5 years, and no clear indication for,
or contraindication to, treatment with an angiotensin-converting
enzyme inhibitor were recruited from 172 centers in 10 countries
between 1995 and 1997. There were no study inclusion or exclusion
criteria based on pre-specified levels of BP or kidney function.
Informed consent was obtained from all patients, and the study was
conducted according to the Declaration of Helsinki Principles and
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Figure 4 | Age- and sex-adjusted incidence rates of ischemic and hemorrhagic stroke according to achieved follow-up systolic or
diastolic blood pressure levels. Conventions as for Figure 3.
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with the approval of respective institutional research ethics
committees. Baseline creatinine measurements were available in
6071 (99%) of participants; these formed the overall study group for
these analyses.
Randomized treatment
Eligible participants received perindopril during a 4-week open–-
label, active run-in period. Participants who tolerated and adhered
to this treatment were subsequently randomly allocated to active
therapy or matching placebo. Active treatment comprised a flexible
treatment regimen based on perindopril (4 mg daily) in all
participants, with the addition of indapamide (2.5 mg daily; or
2 mg daily in Japan) for patients with no specific indication for, nor
contraindication to, the use of a diuretic. Participants who were
assigned placebo received one or two tablets identical in appearance
to the active agents.
Follow-up
Participants were seen at entry, randomization, and at 1, 3, 6, 9, and
12 months in the first year after randomization. In the second and
subsequent years, follow-up was 6 months.
Kidney function
Serum creatinine was measured at local laboratories.
Creatinine clearance was estimated using the Cockroft Gault
Equation:23
Creatinine clearance ¼ Að140  ageÞweight=ð72creatinineÞ
where creatinine clearance is in ml min1, age in years, serum
creatinine in mg per 100 ml, and weight in kg. A¼ 1 for men and
0.85 for women.
Participants with CKD were defined as those with an estimated
creatinine clearance below 60 ml min1.24
Blood pressure measurements
Blood pressure was measured in the seated position at every visit, to
the nearest 2 mm Hg, using a standard mercury sphygmoman-
ometer. Duplicate recording were taken, with an interval of at least
2 min after 5 min of quiet rest, and the mean of the two
measurements was recorded. Ordinal categories of SBP and DBP
were defined as follows: SBP o120, 120–139, 140–159, and
X160 mm Hg; DBP o70, 70–79, 80–89, and X90 mm Hg. As few
participants had baseline SBP o120 mm Hg or baseline DBP
o70 mm Hg, these groups were combined with participants in the
group having SBP 120–139 or DBP 70–79 mm Hg.
Outcomes
The primary outcome for this analysis was total stroke, defined as a
neurological deficit lasting at least 24 h (International Classification
of Diseases 9th revision code 431, 433, 434, 436, and 437).25 Strokes
were further subclassified as ischemic (code 433 and 434) or
hemorrhagic (code 431). Only the first event of the relevant
outcome type was included in each analysis. There were a relatively
small number of unclassified subtype strokes (code 436 and 437) in
patients with CKD, so that separate analysis of this end point could
not be reliably performed.
Statistical methods
Differences in mean values of continuous variables and frequencies
of categorical variables were examined using Student’s t-test and w2
test, respectively. The effects of randomized treatment on the risk of
stroke, or its subtypes, were calculated using univariate Cox’s
proportional hazards models, according to the principle of intention
to treat. As the overall effect of treatment was greater among
participants treated with combination therapy (perindopril and
indapamide vs double placebo) than those treated with single-drug
therapy (perindopril vs single placebo), treatment effects in
subgroups were standardized for the proportions of the study
population for whom combination (58%) or single-drug therapy
(42%) was prescribed, by taking weighted averages of the estimates
obtained for the two therapies.25 Comparisons of treatment effects
across the BP categories, or between participants with and without
CKD at each baseline BP level, were performed by adding an
interaction term to Cox proportional hazards models. The overall
treatment effect was assumed to be present for all particular
subgroups, unless a significant interaction between the treatment
effect and BP levels in the subgroups was observed.
Associations of achieved follow-up BP levels with the risk of
stroke were assessed using the pooling of repeated observations
method.26,27 Each participant’s follow-up was divided into a series
of intervals defined by the follow-up visits. For each interval, the BP
level recorded at the commencement of the interval was assigned,
and the presence or absence of the relevant outcome during each
interval was documented. Missing follow-up BP values were
imputed as the BP values recorded in the previous visit. The 6071
participants generated 62 361 intervals with follow-up SBP and DBP
levels for the intervals ranging from 74 to 242 mm Hg and 41 to
140 mm Hg, respectively. These intervals were divided into four
ordinal achieved follow-up BP groups. For SBP: o120, 120–139,
140–159, and X160 mm Hg, with median values of 112, 130, 148,
and 168 mm Hg in participants with CKD, and 113, 130, 147, and
167 mm Hg in participants without CKD. For DBP: o70, 70–79,
80–89, and X90 mm Hg, with median values of 64, 74, 83, and
93 mm Hg in participants with CKD, and 65, 75, 83, and 93 mm Hg in
participants without CKD. Stroke incidence rates within each group
were calculated using the person-years methods and adjusted for age
and sex using the direct methods. The multivariate-adjusted hazard
ratio for the risk of stroke was estimated using time-dependent Cox’s
proportional hazards models that included potential confounding
factors. Trends in relationships between achieved follow-up BP levels
and the risk of stroke were tested, according to kidney function status,
using each median value of BP for BP group.
The SAS software package (SAS Institute Inc., Cary, NC, USA)
was used to perform all statistical analyses. A P-value below 0.05 was
considered statistically significant.
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